



MedGenome to present on OncoMD, a genomics data analysis and interpretation platform, for cancer discovery research

The MedGenome proprietary platform, currently leveraged by various commercial and academic collaborators in the US, will be presented at AACR 2016.



FOSTER CITY, CALIFORNIA, UNITED STATES, March 30, 2016 /EINPresswire.com/ -- MedGenome will present an abstract on its proprietary data analysis and interpretation platform for Cancer discovery research at the AACR Annual Meeting 2016, organised by the American Association of Cancer Research which takes place on April 16-20, 2016 at New Orleans, Louisiana, USA.

[OncoMD Cancer Analytics Platform](#) combines tumor mutation profiles, expression signatures, copy number variations, epigenetic alterations and drug sensitivity to create a holistic view of human cancer enabling discovery of new targets for therapy and prognosis. The rich mutational data captured in OncoMD, more than 1.9 million and growing, helps to identify potential T-cell neo-epitopes in different cancers and broadens our understanding of their prevalence in the context of the tumor microenvironment, which could be relevant biomarkers of response for immunotherapy drugs. The powerful data analysis and interpretation offered by OncoMD enable extraction of disease-relevant information from diverse genomics data to guide diagnosis and treatment decisions.

MedGenome offers OncoMD to its customers as an enterprise installation or as a plug-and-play software to the existing pipeline at the customer end. A custom version of the platform, [OncoMD Lite](#), is available as a free license to academic researchers for a limited period.

About MedGenome

MedGenome (<http://www.medgenome.com>) is a genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual's genome. Its unique access to genomics data with clinical and phenotypic data provides insights into complex diseases at the genetic and molecular level to facilitate research in personalized health care. MedGenome is a market leader for genomic diagnostics in South Asia and a leading provider of genomics research services globally.

Forward-looking Statements:

This document contains certain forward-looking statements, other than the statements of research facts contained in this press release are forward looking statements. Terms such as "believe", "estimate", "anticipate", "plan", "predict", "may", "hope", "can", "will", "should", "expect", "intend", "is designed to", "with the intent", "potential", the negative of these words or such other variations thereon or comparable terminology, may indicate forward-looking statements, but their absence does

not mean that a statement is not forward-looking. These forward-looking statements speak only as of the date of this press release. The events and circumstances reflected in MedGenome's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, MedGenome does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Hiranjith GH
MedGenome
+91-7022020883
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.